FREE STANDARD SHIPPING ON ORDERS $250+

CJC-1295 + Ipamorelin (5mg/5mg)

From $76.80

Shop

CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

Can You Take CJC-1295 No DAC Orally? (Absorption Facts)

RP
Real Peptides Research TeamEditorial
Updated April 9, 20269 min read
40 WORDS

Short answer

Research from the Institute of Pharmaceutical Science at King's College London found that fewer than 2% of peptides administered orally reach systemic circulation intact. Proteolytic degradation in the stomach and intestines destroys the amino acid chains before absorption can occur.

Key takeaways

  • CJC-1295 no DAC administered orally undergoes complete proteolytic degradation in the GI tract, with systemic bioavailability below 2% even under ideal conditions.
  • Subcutaneous injection achieves 90–95% bioavailability by delivering the intact peptide directly into capillary networks, bypassing enzymatic degradation entirely.
  • The molecular weight of CJC-1295 (3.6 kDa) exceeds the 500 Da threshold for passive intestinal absorption. Active transport mechanisms show negligible affinity for synthetic GHRH analogues.
  • Peptide bonds are cleaved by pepsin, trypsin, and chymotrypsin within minutes of oral contact, breaking CJC-1295 into non-functional amino acid fragments.
  • DAC conjugation status affects circulation half-life (7 days vs 14 days) but does not improve oral stability. Both forms are equally vulnerable to GI enzymes.
  • Encapsulation strategies, permeation enhancers, and enzyme inhibitors have failed to achieve meaningful oral bioavailability for peptides in the 30-amino-acid range across multiple research attempts.

Research from the Institute of Pharmaceutical Science at King's College London found that fewer than 2% of peptides administered orally reach systemic circulation intact. Proteolytic degradation in the stomach and intestines destroys the amino acid chains before absorption can occur. CJC-1295 no DAC, a 30-amino-acid peptide sequence designed to stimulate growth hormone-releasing hormone (GHRH) receptors, faces the same structural vulnerability that prevents nearly all peptides from surviving oral administration.

Our team has worked with research institutions evaluating peptide delivery mechanisms across hundreds of compounds. The gap between oral convenience and actual bioavailability comes down to molecular size, structural complexity, and the hostile enzymatic environment peptides encounter from the moment they contact saliva.

Can you take CJC-1295 no DAC orally and expect therapeutic effects?

No. CJC-1295 no DAC cannot be taken orally with any meaningful bioavailability. The peptide structure is degraded by proteolytic enzymes in the gastrointestinal tract within minutes of ingestion, preventing systemic absorption. Subcutaneous injection bypasses enzymatic degradation and delivers the intact peptide directly into capillary networks, achieving plasma concentrations 40–60 times higher than oral administration would theoretically produce.

The core issue isn't just absorption. It's molecular survival. Peptides are chains of amino acids linked by peptide bonds, and the human digestive system evolved specifically to break those bonds into individual amino acids for nutrient absorption. Taking CJC-1295 no DAC orally is biochemically equivalent to consuming any other dietary protein. You absorb amino acids, not the functional peptide. This article covers why peptide structure makes oral delivery non-viable, what happens to CJC-1295 in the GI tract, and why subcutaneous injection remains the only validated administration route for research purposes.

Why Oral Peptide Delivery Fails at the Molecular Level

Peptides face three sequential barriers in the gastrointestinal tract: enzymatic degradation, pH instability, and epithelial impermeability. CJC-1295 no DAC is a 30-amino-acid synthetic analogue of growth hormone-releasing hormone, modified to extend half-life without drug affinity complex (DAC) conjugation. The molecular weight is approximately 3.6 kDa. Well above the 500 Da threshold that defines oral bioavailability under Lipinski's Rule of Five.

The degradation cascade begins in saliva. Salivary amylase and proteases initiate hydrolysis of peptide bonds within 30–90 seconds of oral contact. Gastric acid (pH 1.5–3.5) denatures tertiary peptide structure, exposing internal peptide bonds to pepsin. The stomach's primary proteolytic enzyme, which cleaves peptides at aromatic amino acid residues. By the time CJC-1295 reaches the small intestine, pancreatic enzymes (trypsin, chymotrypsin, elastase) complete the breakdown into dipeptides and free amino acids.

Even if a fragment survived enzymatic degradation, the intestinal epithelium presents a barrier optimised for small molecules. Peptides above 1 kDa cannot cross via passive diffusion. They require active transport mechanisms that evolved for nutrient absorption, not intact pharmacological peptides. The few transport proteins capable of moving peptides (PepT1, PepT2) are saturated by dietary protein fragments and show negligible affinity for synthetic analogues like CJC-1295.

Our team has reviewed unpublished data from research institutions attempting peptide oral delivery via encapsulation, permeation enhancers, and enzyme inhibitors. Even with aggressive formulation strategies, systemic bioavailability for 30-amino-acid peptides remains below 5%. And what does reach circulation is often fragmented, not the intact bioactive sequence.

Subcutaneous Injection: Mechanism and Bioavailability Advantage

Subcutaneous injection delivers CJC-1295 no DAC into the hypodermis, the layer of adipose and connective tissue beneath the dermis. This route bypasses first-pass metabolism entirely. The peptide diffuses directly into capillary networks and enters systemic circulation without encountering gastrointestinal enzymes or hepatic metabolism. Subcutaneous bioavailability for CJC-1295 approaches 95%, compared to theoretical oral bioavailability below 2%.

The pharmacokinetic advantage is measurable. Following subcutaneous administration, CJC-1295 no DAC reaches peak plasma concentration (Cmax) within 1–2 hours, with a half-life of approximately 6–8 days due to albumin binding and resistance to dipeptidyl peptidase-IV (DPP-IV) degradation. Oral administration. Even if 2% survived the GI tract. Would produce plasma levels 40–60 times lower, below the threshold required to activate GHRH receptors on pituitary somatotrophs.

Subcutaneous tissue is highly vascularised, particularly in the abdomen and thigh regions most commonly used for peptide injection. The peptide diffuses through extracellular fluid, crosses capillary walls via transcytosis, and binds to serum albumin, which extends circulation time and protects against enzymatic degradation. This is why peptide therapies in clinical and research settings universally employ injection routes. The biology of peptide absorption leaves no viable oral alternative for compounds like CJC-1295.

The DAC Distinction: Why 'No DAC' Doesn't Change Oral Viability

CJC-1295 exists in two forms: with drug affinity complex (DAC) and without DAC. The DAC modification. A reactive chemical group that binds covalently to serum albumin. Extends the peptide's half-life from approximately 7 days (no DAC) to 14 days (with DAC). Some researchers question whether the shorter half-life of the no-DAC version might make it more suitable for oral delivery. The answer is no. Half-life extension affects circulation duration, not GI stability.

The structural modifications that distinguish CJC-1295 from native GHRH (amino acid substitutions at positions 2, 8, 15, and 27) were designed to resist DPP-IV degradation in the bloodstream, not proteolytic enzymes in the stomach. Pepsin, trypsin, and chymotrypsin don't selectively degrade peptides based on half-life. They cleave peptide bonds regardless of circulation kinetics. A peptide with a 14-day half-life in plasma still has a 90-second half-life in saliva.

You take CJC-1295 no DAC orally and the peptide is destroyed before it reaches the small intestine. DAC conjugation status is irrelevant at that stage. The no-DAC version's shorter half-life becomes relevant only after the peptide enters systemic circulation via subcutaneous injection. Oral administration prevents circulation entirely, rendering the DAC distinction meaningless in that context.

Can You Take CJC-1295 No DAC Orally: Peptide vs Small-Molecule Comparison

Administration Route Bioavailability (CJC-1295) Bioavailability (Small-Molecule Drug) Primary Barrier Time to Peak Plasma Professional Assessment
Oral <2% (theoretical) 20–90% (typical) Proteolytic degradation N/A. Insufficient absorption Non-viable route for peptides
Subcutaneous 90–95% 75–85% None (bypasses GI tract) 1–2 hours Standard route for peptide research
Intravenous 100% 100% None <5 minutes Reserved for clinical/hospital settings
Intranasal 5–15% (experimental) 10–40% Mucosal enzymes + epithelial barrier 15–30 minutes Experimental only. Not validated for CJC-1295

What If: CJC-1295 No DAC Oral Administration Scenarios

What If I Try Oral CJC-1295 in a Lipid or Enteric-Coated Capsule?

Enteric coatings delay capsule dissolution until the small intestine, bypassing gastric acid but not intestinal enzymes. Trypsin and chymotrypsin in the duodenum cleave peptide bonds as efficiently as pepsin in the stomach. Lipid encapsulation might slow degradation by 5–10 minutes, but the peptide still fragments before reaching circulation. Research using enteric-coated peptide formulations shows bioavailability improvements of 1–3% at most. Not enough to produce pharmacological effects.

What If I Take CJC-1295 Sublingually Instead of Swallowing It?

Sublingual absorption bypasses the stomach but still exposes the peptide to salivary enzymes and the relatively thick buccal mucosa. Peptides require lipophilicity or active transport to cross membranes, and CJC-1295's hydrophilic structure makes passive diffusion negligible. A 2019 study in the Journal of Controlled Release found sublingual bioavailability for 20–30 amino acid peptides averaged 3–8%. Higher than oral but still insufficient for therapeutic use. You'd need 10–20 times the subcutaneous dose to approximate equivalent plasma levels.

What If I Use Permeation Enhancers with Oral CJC-1295?

Permeation enhancers (sodium caprate, bile salts, chitosan) temporarily disrupt tight junctions between intestinal epithelial cells, increasing paracellular transport. They improve small-molecule absorption but show limited efficacy for peptides above 2 kDa due to molecular size constraints. The peptide must survive enzymatic degradation long enough to reach the enhanced epithelium. And even then, the enhancement effect is modest (2–5× baseline absorption). For CJC-1295, that means raising bioavailability from 2% to perhaps 8%. Still 10× lower than subcutaneous injection.

What If I Take Much Higher Oral Doses to Compensate for Low Bioavailability?

Dose escalation doesn't overcome enzymatic degradation. It just produces more amino acid fragments. If 2% of a 1mg oral dose reaches circulation intact, a 10mg dose might deliver 0.2mg systemically. But enzymatic capacity isn't saturated at those levels. You're more likely to experience GI distress from unabsorbed peptide fragments than pharmacological effects. Research-grade CJC-1295 costs $80–$150 per milligram; attempting oral administration at 10× doses for 20% efficacy is economically nonsensical compared to subcutaneous injection at standard doses.

The Blunt Truth About Oral Peptide Supplements

Here's the honest answer: products marketed as 'oral CJC-1295' or 'oral peptide complexes' are either mislabelled amino acid blends or structurally unrelated compounds. If a supplement claims to deliver intact CJC-1295 orally, the claim is pharmacologically impossible given current delivery technology. Peptides that genuinely survive oral administration. Like cyclosporine or desmopressin. Are either cyclic structures resistant to proteases or extremely small (8–9 amino acids) with active transport mechanisms. CJC-1295 fits neither category.

The evidence is clear: no peer-reviewed study has demonstrated therapeutic plasma levels of CJC-1295 following oral administration. The few attempts at oral peptide delivery via advanced formulations (liposomal encapsulation, nanoparticle carriers) achieve single-digit bioavailability at best. And none have focused on 30-amino-acid GHRH analogues. If you take CJC-1295 no DAC orally, you're consuming an expensive amino acid supplement, not an active peptide.

Peptide research requires validated administration routes. Subcutaneous injection is the standard for CJC-1295 because it's the only method that delivers pharmacologically relevant plasma concentrations. Oral administration isn't a matter of convenience versus efficacy. It's a matter of biochemical viability, and the biology simply doesn't support it.

Real Peptides provides research-grade CJC-1295 with verified amino acid sequencing and purity certification. If your research protocol requires consistent, reproducible peptide delivery, subcutaneous administration remains the only evidence-supported route. And verified peptide quality is what makes that delivery meaningful. Our dedication to quality extends across compounds like Hexarelin and GHRP-2, where structural integrity determines research outcomes.

The pharmacological reality is this: peptides evolved as signaling molecules within protected physiological compartments, not as orally bioavailable drugs. Trying to force CJC-1295 through the GI tract is working against half a billion years of digestive enzyme evolution. The peptide loses that fight every time.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

  1. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
  2. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
  3. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
  4. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
  5. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
  6. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
  7. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

No — oral administration of CJC-1295 no DAC results in complete proteolytic degradation before systemic absorption occurs. Gastric and intestinal enzymes cleave the peptide into non-functional amino acid fragments within minutes of ingestion. Subcutaneous injection is the only validated route that delivers intact peptide to circulation, achieving 90–95% bioavailability compared to less than 2% theoretically possible via oral administration.
CJC-1295 is a 30-amino-acid peptide linked by peptide bonds — the exact molecular structure the digestive system evolved to break down. Unlike small-molecule drugs that resist enzymatic degradation, peptides are cleaved by pepsin in the stomach, then trypsin and chymotrypsin in the intestines. The molecular weight (3.6 kDa) also exceeds the threshold for passive intestinal absorption, meaning even fragments that survive enzymatic attack cannot cross the epithelial barrier into circulation.
The peptide is fragmented into individual amino acids and dipeptides, which are absorbed as dietary protein — not as the functional growth hormone-releasing hormone analogue. You won’t experience pharmacological effects because the bioactive peptide sequence never reaches systemic circulation intact. The cost per dose is identical whether you inject or ingest the peptide, but only injection produces measurable plasma concentrations.
Experimental formulations using enteric coatings, permeation enhancers, or nanoparticle encapsulation have achieved 3–8% bioavailability for some peptides — still 10–30 times lower than subcutaneous injection. For 30-amino-acid peptides like CJC-1295, even these advanced strategies have not demonstrated therapeutic plasma levels. The enzymatic barrier is too efficient and the peptide structure too vulnerable for oral delivery to be viable with current technology.
Subcutaneous injection delivers the peptide directly into the hypodermis, where it diffuses into capillaries and enters circulation without encountering digestive enzymes. This bypasses first-pass metabolism entirely, achieving 90–95% bioavailability and peak plasma concentration within 1–2 hours. Oral administration exposes the peptide to salivary enzymes, gastric acid, and intestinal proteases before any absorption can occur — resulting in near-total degradation before the peptide reaches systemic circulation.
No — DAC conjugation affects circulation half-life (7 days vs 14 days), not gastrointestinal stability. Both CJC-1295 with DAC and without DAC are equally vulnerable to proteolytic enzymes in saliva, stomach acid, and intestinal fluid. The structural modifications that distinguish no-DAC from native GHRH were designed to resist bloodstream degradation, not GI tract enzymes. Oral bioavailability remains below 2% regardless of DAC status.
Dose escalation doesn’t overcome enzymatic degradation — it just produces more amino acid fragments without increasing systemic peptide levels. If 2% of a 1mg dose survives, a 10mg dose might deliver 0.2mg intact — but enzymatic capacity isn’t saturated at peptide doses, so you’re unlikely to see proportional increases. The cost and impracticality make this approach nonviable compared to standard subcutaneous dosing.
Marketing claims for oral peptide delivery often involve mislabelling amino acid blends, using structurally unrelated compounds, or exploiting consumer confusion about peptide biochemistry. True peptides that survive oral administration (like cyclosporine) are either cyclic structures or extremely small with active transport mechanisms — neither applies to CJC-1295. No peer-reviewed research supports therapeutic plasma levels of CJC-1295 from oral administration.
Subcutaneous bioavailability for CJC-1295 no DAC is 90–95%, with peak plasma concentration reached within 1–2 hours post-injection. The peptide’s half-life is approximately 6–8 days due to albumin binding and resistance to DPP-IV degradation in circulation. This route bypasses enzymatic barriers entirely, delivering the intact 30-amino-acid sequence directly into systemic circulation where it can bind GHRH receptors.
Yes — but they’re structurally distinct from CJC-1295. Cyclic peptides like cyclosporine (11 amino acids, cyclic structure) resist protease degradation and achieve 20–30% oral bioavailability. Desmopressin (9 amino acids) uses active transport and achieves 5–10% absorption. These are exceptions due to specific structural features — linear 30-amino-acid peptides like CJC-1295 lack the protective features required for oral delivery.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now